TD Securities Issues Positive Forecast for Extendicare (TSE:EXE) Stock Price

Extendicare (TSE:EXEGet Free Report) had its target price boosted by investment analysts at TD Securities from C$9.50 to C$10.50 in a report released on Thursday,BayStreet.CA reports. TD Securities’ target price points to a potential upside of 3.86% from the stock’s current price.

Separately, Royal Bank of Canada raised their target price on shares of Extendicare from C$8.50 to C$9.50 in a report on Monday, August 19th.

Check Out Our Latest Stock Analysis on Extendicare

Extendicare Price Performance

Shares of EXE traded down C$0.07 on Thursday, reaching C$10.11. The stock had a trading volume of 88,567 shares, compared to its average volume of 134,313. Extendicare has a twelve month low of C$6.41 and a twelve month high of C$10.43. The firm has a market capitalization of C$843.88 million, a PE ratio of 14.87 and a beta of 1.26. The firm has a 50-day moving average of C$9.21 and a 200 day moving average of C$8.12. The company has a quick ratio of 0.98, a current ratio of 0.60 and a debt-to-equity ratio of 305.80.

Extendicare (TSE:EXEGet Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported C$0.29 earnings per share for the quarter. Extendicare had a return on equity of 60.00% and a net margin of 4.28%. The business had revenue of C$348.48 million during the quarter, compared to analysts’ expectations of C$360.20 million. Sell-side analysts expect that Extendicare will post 0.6134729 EPS for the current year.

About Extendicare

(Get Free Report)

Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.

Featured Articles

Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.